Carey Olsen’s investment funds team in Guernsey has advised venture capital and growth equity firm Endeavour Vision on the successful launch and final close of its second dedicated medtech and digital health fund, Endeavour Medtech Growth II (EMG II) LP, with commitments of US$375 million.
The EMG II LP fund will continue the strategy of its US$250 million predecessor (Endeavour Medtech Growth LP) by investing in high-potential European and US companies delivering transformative healthcare technologies to improve the standard of care for patients and bring efficiencies to healthcare systems. In particular, the fund will focus on growth stage companies that have overcome clinical and regulatory hurdles and are starting to generate commercial traction.
Working alongside Clifford Chance (Munich), partner David Crosland with assistance from senior associate Alex Mauger led the Carey Olsen team that advised Endeavour Vision on all Guernsey aspects of the fund’s establishment, regulation, launch and closing.
David said: “The medtech sector continues to evolve rapidly and we’re delighted to have assisted Endeavour Vision on the launch of its latest fund which will invest in innovative medtech and digital health solutions to shape the future of healthcare. The successful fundraising demonstrates the high level of confidence in Endeavour as a market-leading investor in this dynamic and vibrant field.”
